Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zegerid May Bring Quick Heartburn Relief To Market Under Santarus/S-P deal

This article was originally published in The Tan Sheet

Executive Summary

Immediate-release delivery will give Santarus' proton pump inhibitor Zegerid (omeprazole/sodium bicarbonate) an edge against Prilosec OTC in the heartburn market if the firm can pull off a planned Rx-to OTC switch

Related Content

Zegerid OTC Approved, Limited To Touting Dual-Ingredient Formula For Now
Zegerid Switch Progress Generates Bottom Line Help For Santarus
Zegerid Switch Application Expected Before May – Santarus
Zegerid Study Shows Benefits For Immediate-Release PPI/Antacid
S-P/Santarus deal
Clarinex OTC Option “Valuable” In Face Of Competition – Schering-Plough
S-P Brings New Laxative Class To OTC Market Under Braintree Licensing Deal
Zegerid deal solidifies
Zegerid sales force
TAP Licenses Prevacid To Novartis For 2009 Switch





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts